SparkyReturns Posted - 1 day ago

$ALNY So, here's an Investing Idea: XERIS already has collabs with big pharma REGN and AMGN. Will your company be next to use their delivery tech to replace long infusions with high concentration SubQ delivery? AMGN even ditched HALO recently to go with XERS delivery system instead for Tepezza because higher concentrations and no need for refrigeration. Time is running out to get in below 2.50. Why am I so optimistic? 1. Stable and growing revenue base. Gvoke and Recorlev will report highest sales ever at next ER on Aug 8. 2. SubQ Levo XP-8121(thyroid treatment) will solve administration issues for people with gastro issues/pills, $2-3B TAM. XERS has hinted about bringing on a partner to monetize value. 3. Will hear soon on collabs with Amgen, Regeneron, and Beta Bionics and will learn soon what the terms are of their upfront payments and milestone payments. 4. Tutes have been quietly loading up under 2.50, highest institutional ownership ever. Cheers! $BAYRY $TEVA $ARGX

intratio Posted - 4 days ago

https://www.intratio.com/stock-forecast/ALNY Our statistical model concludes the value of this equity clearly has a bad short-term setup and, in the long run, faces severe disadvantages $ALNY

intratio Posted - 6 days ago

ALNYLAM PHARMACEUTICALS, INC. The artificial intelligence lets us believe that this stock s price action will drop in the coming days and is poised to drop further in the coming weeks $ALNY

Silverstein3686 Posted - 1 week ago

@NewMexicats Great find on $BVAXF. This theme fits in with other Biotech companies like $NWBO and $ALNY

zimmerman53 Posted - 1 week ago

$ALNY Who is excited for results for Alnylam P5x25 next year?

universeisgr8 Posted - 1 week ago

$ALNY LOL how ironic algo scam....i knew they would pump it back today so bought calls for cents when it dip below 235 which are now printing.

EPSMomentumStocks Posted - 1 week ago

Powerful institutional buying on these names $ALNY $ADBE $FCNCA $TPL $UTHR

frontiere Posted - 1 week ago

$ALNY $BBIO $CYTK $NTLA $PFE if anyone wonders why today’s price pressure — ICER draft report re ATTR-CM came out saying therapies cause marginally more hospitalizations than supportive care alone Report https://icer.org/wp-content/uploads/2024/07/ATTR-CM_Draft-Report_For-Publication_07172024.pdf Public comment & webinar news https://icer.org/news-insights/press-releases/icer-releases-draft-evidence-report-on-treatments-for-transthyretin-amyloid-cardiomyopathy/

Stock_Titan Posted - 1 week ago

$ALNY Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2024-cj1ct20p0y6x.html

Avocado_smash Posted - 1 week ago

$ALNY .

BP_Investor Posted - 1 week ago

$ALNY it’s time to buy short term put

PeedyWeedy Posted - 1 week ago

$ALNY How much will the Helios data move the needle?

zimmerman53 Posted - 1 week ago

$ALNY still feels like moderate upside. But does feel fully valued up here!

insiderbuyingselling Posted - 2 weeks ago

$ALNY new insider selling: 7093 shares. http://insiderbuyingselling.com/?t=ALNY

frontiere Posted - 2 weeks ago

$BBIO BridgeBio exited today ref=$27.50 common shares from entries=~$22.00 just 2.5 weeks ago. + exited calls Aug exp $25 strike bought near those lows. (BTW - IV was too high on entry, should’ve just bought equiv delta in commons). PaYtience paid off fast. Why exit now? Long term bull target is in the $50’s, but: 1- reached pre HELIOS-B levels, could be resistance till 30 Aug ECS $ALNY full data? 2- let’s see what macro backdrop brings between now and then… 3- $BBIO Acoramidis PDUFA is due 29 Nov , if Aug clears well can re-buy even higher for the next good catalyst. +still holding short Alnylam at a loss, seems better r:r on overreactions when oversold/to buy rather than overbought/short. But fundamentally conviction that it will revert. Also relevant $ALNY $CYTK $NTLA $PFE

Deshann2 Posted - 2 weeks ago

$ALNY starting the day excellently, winning very early $VIRI

DocPharm Posted - 2 weeks ago

$ALNY

IsabellaDC Posted - 2 weeks ago

$ALNY remains on the more cycle

Utilde Posted - 2 weeks ago

$KZIA $TWST $ALNY $ILMN $JNJ

TheGrandExchange Posted - 2 weeks ago

$ALNY impervious to the broader market apparently

davidmoadel Posted - 2 weeks ago

35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. -- article I wrote for @investorplace https://investorplace.com/2024/07/35-surge-just-the-beginning-alnylams-stock-poised-for-massive-gains-on-heart-drug-success/ $ALNY

davidmoadel Posted - 2 weeks ago

35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. -- article I wrote for @investorplace https://investorplace.com/2024/07/35-surge-just-the-beginning-alnylams-stock-poised-for-massive-gains-on-heart-drug-success/ $ALNY

Brabus90000 Posted - 2 weeks ago

$ALNY the Bateman Horne Center conducted an open label, proof-of-concept trial of IMC-2 in patients with Long COVID and showed that patients experienced clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction. Importantly, the combination of valacyclovir/celecoxib was well tolerated as there were no serious adverse events and the side effect profile was consistent with what is known for both valacyclovir and celecoxib. The following table gives an overview of the results for various study endpoints examined, the majority of which statistically significantly favored valacyclovir/celecoxib. $VIRI

HNInversor Posted - 2 weeks ago

🌟 $ALNY announced positive Phase 2 results for zilebesiran, reducing blood pressure significantly. Their cutting-edge RNAi platform is transforming medicine. Invest in $ALNY and also watch $VIRI for breakthroughs in antiviral research. #InnovativeMedicine #InvestSmart

Vicenti01 Posted - 2 weeks ago

🚀 $ALNY is making waves with a massive 32% stock surge following their groundbreaking results in the Phase 3 HELIOS-B study of vutrisiran, a potential game-changer for ATTR amyloidosis with cardiomyopathy. This RNAi therapeutic not only met its primary endpoint but also demonstrated significant improvements across all secondary endpoints. 📈 With such promising advancements, $ALNY is poised for exceptional growth. Now is the time to ride the biotech wave! And don’t forget to keep an eye on $VIRI, another promising player in the biotech space with their innovative approaches to antiviral therapies. #BiotechBoom #RNAiRevolution

BriamG316 Posted - 2 weeks ago

$VIRI $KZIA $ALNY I buy and expect results, great potential.

Jesu1431 Posted - 2 weeks ago

Take a look at $VIRI! Support zone again! Perfect to buy and hold more and more. $ALNY

Zaidf Posted - 2 weeks ago

$ALNY i think its over for now im selling short, and putting some more in $VIRI

Sr_wasabi Posted - 2 weeks ago

$KZIA $ALNY Working to achieve the volume you need $VIRI 👀

AnaChart Posted - 2 weeks ago

$ALNY https://anachart.com/wp-content/uploads/ana_temp/1720465324_soc-img.jpg